Organism: Homo sapiens
Gene: 39396_at
Selected probe(set): 212449_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39396_at (212449_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-4.4111443
Number of Samples:3 / 3

Experimental	oncolytic herpes simplex virus study 2
	Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control	mock infected peripheral nerve sheath tumor (S462) cell sample
	Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

Relative Expression (log2-ratio):-3.1676617
Number of Samples:2 / 5

Experimental	kidney transplantation study 15 (8 week)
	CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control	normal monocyte (CD14+) sample
	CD14+ monocyte samples derived from healthy control subjects.

Relative Expression (log2-ratio):2.4691877
Number of Samples:8 / 205

Experimental	Huntington's disease study 16 (batch L)
	Blood samples obtained from Huntington´s disease patients (batch L).
Control	Parkinson's disease study 32 (IPD)
	Blood samples obtained from patients with idiopathic Parkinson's disease (IPD). All patients were treated with dopaminergic medication and met United Kingdom Parkinson’s Disease Society Brain Bank Criteria except that positive family history was not regarded as an exclusion criterion. Patients that were suspected of having possible secondary causes for parkinsonism such as use of neuroleptic agents, and patients meeting criteria for atypical PD syndromes and who had SPECT data available that showed scans without evidence of dopaminergic deficits were excluded.

Relative Expression (log2-ratio):2.4672356
Number of Samples:8 / 231

Experimental	Huntington's disease study 16 (batch L)
	Blood samples obtained from Huntington´s disease patients (batch L).
Control	control blood sample
	Blood samples obtained from healthy subjects including nonconsanguineous controls from families of patients.

Relative Expression (log2-ratio):2.4380207
Number of Samples:4 / 2

Experimental	glioma study 27 (glioblastoma, NOS)
	Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma).
Control	glioma study 27 (pilocytic astrocytoma)
	Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma).

Relative Expression (log2-ratio):-2.200389
Number of Samples:7 / 8

Experimental	dendritic cell study 6 (gardiquimod)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (untreated)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):-2.1969118
Number of Samples:4 / 3

Experimental	tumor supernatant activation study 3
	Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control	memory T-cell activation study 1
	Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs.

Relative Expression (log2-ratio):-2.140603
Number of Samples:4 / 8

Experimental	dendritic cell study 6 (gardiquimod; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (untreated)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):2.0701542
Number of Samples:4 / 3

Experimental	rheumatoid arthritis study 31
	Monocyte samples isolated from patients with rheumatoid arthritis (RA). Monocytes from whole blood were depleted from granulocytes by CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. Patients fulfilled the revised American College of Rheumatology criteria (ACR) for RA.
Control	TNF-ɑ study 20
	Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling.

Relative Expression (log2-ratio):2.0288458
Number of Samples:10 / 5

Experimental	kidney transplantation study 11 (12 week)
	Whole blood samples derived from kidney transplant patients 12 weeks post-transplantation. Samples were collected 12 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control	normal blood sample
	Blood samples derived from healthy control subjects.